Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | CRHR1 | P34998 | 6/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.33 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.32 |
| ▸ | BRD4 | O60885 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7562834 | 0.85 | CRHR1 (0.45) | ALDH1A1KDM4EHTTCRHR1CYP1A2 | |
| SCHEMBL7564260 | 0.83 | CRHR1 (0.47) | CRHR1 | |
| SCHEMBL7563165 | 0.80 | CRHR1 (0.33) | KDM4ECRHR1BRD4 | |
| SCHEMBL7562041 | 0.80 | CRHR1 (0.47) | CRHR1 | |
| SCHEMBL7563197 | 0.80 | CRHR1 (0.40) | ALDH1A1KDM4EHPGDCRHR1MAPK1 | |
| SCHEMBL7562809 | 0.76 | CRHR1 (0.47) | CRHR1 | |
| SCHEMBL7561996 | 0.74 | NPC1 (0.47) | ALDH1A1TSHRKDM4EHPGDHTT | |
| SCHEMBL7590936 | 0.72 | PDE1B (0.39) | CRHR1 | |
| SCHEMBL7591990 | 0.69 | TP53 (0.43) | ALDH1A1KDM4EHPGDCRHR1 | |
| SCHEMBL5787033 | 0.66 | CRHR1 (0.36) | KDM4EHTTCRHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020065290-A1 | Novel deazapurine derivatives: a new class of CRF1 specific ligands | NEUROGEN CORPORATION | 2002-05-30 | — | — | US | claimed |
| EP-0770080-B1 | NOVEL DEAZAPURINE DERIVATIVES; A NEW CLASS OF CRF1 SPECIFIC LIGANDS | NEUROGEN CORP (US) | 1999-07-14 | — | — | EP | claimed |
| US-5644057-A | Deazapurine derivatives; a new class of CRF1 specific ligands | NEUROGEN CORPORATION (US) | 1997-07-01 | — | — | US | claimed |
| WO-1996035689-A1 | NOVEL DEAZAPURINE DERIVATIVES; A NEW CLASS OF CRF1 SPECIFIC LIGANDS | NEUROGEN CORPORATION (US) | 1996-11-14 | — | — | WO | claimed |
| US-6495688-B2 | USED AS CORTICOTROPIN-RELEASING FACTOR (CRF) ANTAGONISTS, IN THERAPY AND DIAGNOSIS OF STRESS RELATED DISORDERS SUCH AS POST TRAUMATIC STRESS DISORDER (PTSD) AS WELL AS DEPRESSION, HEADACHE AND ANXIETY | NEUROGEN CORPORATION | 2002-12-17 | — | — | US | disclosed |
| US-20020065290-A1 | Novel deazapurine derivatives: a new class of CRF1 specific ligands | NEUROGEN CORPORATION | 2002-05-30 | — | — | US | disclosed |
| US-6281220-B1 | PYRROLO(3,2-D)PYRIMIDIN-4-AMINES AND PYRROLO(3,2-B)PYRIDIN-4-AMINES, AND THEIR USE AS ANTAGONISTS OF CORTICOTROPIN-RELEASING FACTOR | NEUROGEN CORPORATION | 2001-08-28 | — | — | US | disclosed |
| US-6020492-A | Deazapurine derivatives; a new class of CRF1 specific ligands | NEUROGEN CORPORATION (US) | 2000-02-01 | — | — | US | disclosed |
| EP-0770080-B1 | NOVEL DEAZAPURINE DERIVATIVES; A NEW CLASS OF CRF1 SPECIFIC LIGANDS | NEUROGEN CORP (US) | 1999-07-14 | — | — | EP | disclosed |
| US-5644057-A | Deazapurine derivatives; a new class of CRF1 specific ligands | NEUROGEN CORPORATION (US) | 1997-07-01 | — | — | US | disclosed |
| WO-1996035689-A1 | NOVEL DEAZAPURINE DERIVATIVES; A NEW CLASS OF CRF1 SPECIFIC LIGANDS | NEUROGEN CORPORATION (US) | 1996-11-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020065290-A1 | Novel deazapurine derivatives: a new class of CRF1 specific ligands | CRHR1, CRH, CRHR2 | ALDH1A1 674/4885TSHR 667/4885KDM4E 3816/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.